EUVIMEDScopri EUVIMED
Crossref

Investigating the Challenges of Managing Coexisting Subglottic Stenosis and Bronchopulmonary Diseases Medically Using Computational Modeling

Kerry Gao, Nathan A Luzum, Seth Cohen, Dennis O Frank-Ito iD

Otolaryngology–Head and Neck Surgery · 2026

DOI: 10.1002/ohn.70097 ↗

At a glance

Journal article in Otolaryngology–Head and Neck Surgery, 2026. Written by Kerry Gao and 3 co-authors. Institution: Duke University School of Medicine, Durham, North Carolina, USA. Major MEDLINE topics: Laryngostenosis, Computer Simulation, Fluticasone, Pregnenediones. 26 references.

AbstractSubjectsDati bibliograficiCiteRelated studies

Abstract (original language)

Objective

Subglottic stenosis (SGS) coexists with bronchopulmonary disease, complicating topical therapy given the distinct anatomical targets. Optimizing inhaled medication delivery to both regions remain a therapeutic challenge. This study evaluates the ability of orally inhaled aerosol particles to achieve dual‑site deposition in SGS and bronchopulmonary regions. Study Design Computational modeling of orally inhaled drug particle delivery.

Setting

Academic Medical Center.

Methods

Digitally modified airways simulating 8 SGS variants, combining McCaffrey Stage I (5 mm) and II (15 mm) subglottic lengths with Cotton‑Myer Grade I (10%, 30%), Grade II (60%), and Grade III (90%) luminal constrictions. Oral inhalation at 15 L/min and particle transport were simulated for fluticasone propionate (FP; mean aerosol velocity 9.19 m/s, particle size range 1‐8 μm) and ciclesonide (CIC; mean aerosol velocity 4.26 m/s, particle size range 1‐4 μm) inhaler characteristics, and 6 particle‑size distributions M 1 (1‐5 μm), M 2 (6‐10 μm), M 3 (1‐10 μm) while maintaining the respective parent (CIC and FP) mean aerosol velocity.

Results

In the normal airway, CIC and FP inhalers achieved >80% bronchial deposition but ≤0.02% subglottic delivery. Among modified devices, M 2 CIC optimized dual targeting, providing the highest subglottic deposition (0.09%) with preserved bronchial efficiency (69.46%). In SGS models, M 2 CIC and M 2 FP consistently achieved the most balanced delivery, with maximum deposition of M 2 CIC = 8.4% and M 2 FP = 7.86% at subglottic region, and M 2 CIC = 69.89% and M 2 FP = 61.02% at bronchial site. M 3 variants offered intermediate dual deposition at advanced and Grade III stenosis stages.

Conclusion

M 2 CIC and M 2 FP inhaler modifications optimized dual‐site supporting tailored device strategies for SGS with coexisting bronchopulmonary disease.

Subjects

MeSH terms (MEDLINE)

LaryngostenosisComputer SimulationFluticasonePregnenedionesHumansAdministration, InhalationAerosolsDrug Delivery Systems

Author keywords

bronchopulmonarycomputational modelmedicationorally inhaledsubglottic stenosis

Substances

FluticasoneAerosolsPregnenedionesciclesonide

Authors and institutions

  • Duke University School of Medicine, Durham, North Carolina, USA.
  • Department of Head and Neck Surgery & Communication Sciences, Duke University, Durham, North Carolina, USA.

ORCID profiles: Dennis O Frank-Ito

Cite

APA

Gao, K., Luzum, N. A., Cohen, S., & Frank-Ito, D. O. (2026). Investigating the Challenges of Managing Coexisting Subglottic Stenosis and Bronchopulmonary Diseases Medically Using Computational Modeling. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.70097

Vancouver

Gao K, Luzum NA, Cohen S, Frank-Ito DO. Investigating the Challenges of Managing Coexisting Subglottic Stenosis and Bronchopulmonary Diseases Medically Using Computational Modeling. Otolaryngology–Head and Neck Surgery. 2026. doi:10.1002/ohn.70097

BibTeX
@article{Gao2026,
  author = {Gao, Kerry and Luzum, Nathan A and Cohen, Seth and Frank-Ito, Dennis O},
  title = {Investigating the Challenges of Managing Coexisting Subglottic Stenosis and Bronchopulmonary Diseases Medically Using Computational Modeling},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2026},
  doi = {10.1002/ohn.70097}
}
Start for free →